These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9489092)

  • 1. The medical treatment of patients presenting with intermittent claudication secondary to atherosclerosis.
    Sandison AJ; Taylor PR
    Int J Clin Pract; 1997; 51(5):313-5. PubMed ID: 9489092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating claudication in 5 words (stop smoking and keep walking) is no longer enough: an audit of risk factor management in patients prescribed exercise therapy in New Zealand.
    Kuiper N; Gordon M; Roake J; Lewis D
    N Z Med J; 2006 Mar; 119(1231):U1918. PubMed ID: 16582978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral artery disease: therapeutic advances.
    Shamoun F; Sural N; Abela G
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):539-53. PubMed ID: 18402543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and medical management of patients with intermittent claudication.
    LaPerna L
    J Am Osteopath Assoc; 2000 Oct; 100(10 Su Pt 2):S10-4. PubMed ID: 11105462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment and management of intermittent claudication: importance of secondary prevention.
    Donnelly R
    Int J Clin Pract Suppl; 2001 Apr; (119):2-9. PubMed ID: 11355275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical treatment of peripheral arterial disease: a comprehensive review.
    Stoyioglou A; Jaff MR
    J Vasc Interv Radiol; 2004 Nov; 15(11):1197-207. PubMed ID: 15525738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of peripheral arterial disease.
    Scott DF
    Aust Fam Physician; 1979 Jul; 8(7):694-9. PubMed ID: 485958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal risk factor modification and medical management of the patient with peripheral arterial disease.
    Chi YW; Jaff MR
    Catheter Cardiovasc Interv; 2008 Mar; 71(4):475-89. PubMed ID: 18307227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of intermittent claudication: the importance of secondary prevention.
    Donnelly R; Yeung JM
    Eur J Vasc Endovasc Surg; 2002 Feb; 23(2):100-7. PubMed ID: 11863326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1).
    Jaff MR; Dale RA; Creager MA; Lipicky RJ; Constant J; Campbell LA; Hiatt WR
    Circulation; 2009 Jan; 119(3):452-8. PubMed ID: 19139383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy and behavioral intervention for peripheral arterial disease.
    Doyle J; Creager MA
    Rev Cardiovasc Med; 2003; 4(1):18-24. PubMed ID: 12684600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study.
    Nenci GG; Gresele P; Ferrari G; Santoro L; Gianese F;
    Thromb Haemost; 2001 Nov; 86(5):1181-7. PubMed ID: 11816704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intermittent claudication--a major cardiovascular risk factor. Proposed guidelines for investigation and treatment].
    Svensson P; Wahlberg E; Hedin U; Ostergren J
    Lakartidningen; 1999 Mar; 96(13):1585-90. PubMed ID: 10218341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intermittent claudication].
    Jensen MB; Nørager CB; Lindholt JS
    Ugeskr Laeger; 2006 Jan; 168(1):43-6. PubMed ID: 16393563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation.
    Bianchi C; Montalvo V; Ou HW; Bishop V; Abou-Zamzam AM
    Ann Vasc Surg; 2007 Mar; 21(2):163-6. PubMed ID: 17349357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating patients with peripheral arterial disease and claudication.
    Treat-Jacobson D; Walsh ME
    J Vasc Nurs; 2003 Mar; 21(1):5-14; quiz 15-6. PubMed ID: 12629492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of walking distance after supervised exercise therapy in patients with intermittent claudication.
    Kruidenier LM; Nicolaï SP; Ten Bosch JA; de Bie RA; Prins MH; Teijink JA
    Eur J Vasc Endovasc Surg; 2009 Oct; 38(4):449-55. PubMed ID: 19540780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Oslo balloon angioplasty versus conservative treatment study (OBACT)--the 2-years results of a single centre, prospective, randomised study in patients with intermittent claudication.
    Nylaende M; Abdelnoor M; Stranden E; Morken B; Sandbaek G; Risum Ø; Jørgensen JJ; Lindahl AK; Arnesen H; Seljeflot I; Kroese AJ
    Eur J Vasc Endovasc Surg; 2007 Jan; 33(1):3-12. PubMed ID: 17055756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intermittent claudications of arterial origin: some epidemiological and physiopathological features].
    Levy JB; Gedeon A
    Phlebologie; 1978; 31(4):357-61. PubMed ID: 740721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.